CAS NO: | 956104-40-8 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
生物活性 | Apalutamide (ARN-509) is a potent and competitiveandrogen receptor(AR) antagonist, binding AR with anIC50of 16 nM[1]. | ||||||||||||||||
IC50& Target | IC50: 16 nM (Androgen receptor)[1] | ||||||||||||||||
体外研究 (In Vitro) | Apalutamide (ARN-509) also exhibits low micromolar affinity (IC503 μM) for the GABAAreceptor in radioligand binding-assays and thus may potentially antagonize GABAAat therapeutic dose levels[1]. Apalutamide is a potent androgen receptor (AR) antagonist that targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets[2]. | ||||||||||||||||
体内研究 (In Vivo) | Apalutamide (ARN-509) exhibits low systemic clearance, high oral bioavailability and long plasma half-life in both mouse and dog, supporting once-daily oral dosing. Consistent with its long terminal-half-life, Apalutamide steady-state plasma-levels increases in repeat-dose studies, resulting in high C24hrlevels and low peak:trough ratios (ratio:2.5). Castrate male mice bearing LNCaP/AR xenograft tumors are treated with either Apalutamide at doses of 1, 10 or 30 mg/kg/day. Thirteen of 20 Apalutamide (30 mg/kg/day)-treated animals exhibit >50% reduction in tumor-volume at day 28 versus 3 of 19 MDV3100 (30 mg/kg/day)-treated mice[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 477.43 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C21H15F4N5O2S | ||||||||||||||||
CAS 号 | 956104-40-8 | ||||||||||||||||
中文名称 | 阿帕鲁胺 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 50 mg/mL(104.73 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|